10,169 results match your criteria Idiopathic Thrombocytopenic Purpura


Sarcoidosis-Associated Immune Thrombocytopenic Purpura and Focal Segmental Glomerulosclerosis.

J Investig Med High Impact Case Rep 2022 Jan-Dec;10:23247096221097522

Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

Sarcoidosis is well known for heterogeneity of its presentation and multisystem organ involvement. It commonly involves respiratory tract, skin, eyes, and lymph nodes, as well as hematologic and renal systems. While anemia and lymphopenia are the most common hematologic abnormalities seen in sarcoidosis, immune thrombocytopenic purpura (ITP) is considered rare. Read More

View Article and Full-Text PDF

Gaucher disease carrier with gestational thrombocytopenia and anemia: a case report.

J Med Case Rep 2022 May 13;16(1):203. Epub 2022 May 13.

Department of Obstetrics, Perinatal Center, National Hospital Organization Kyushu Medical Center, 1-8-1, Jigyohama Chuo-ku, Fukuoka, 810-8563, Japan.

Background: Gaucher disease is an autosomal recessive inborn error of metabolism that causes disorders of blood, bone, and central nervous system as well as hepatosplenomegaly. We present the case of a carrier of Gaucher disease with gestational thrombocytopenia and anemia that required blood transfusion therapy.

Case Presentation: A 24-year-old Nepalese primipara was diagnosed with idiopathic thrombocytopenia at 12 weeks of gestation. Read More

View Article and Full-Text PDF

Seroconversion to mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias and bone marrow failures.

Sci Rep 2022 May 11;12(1):7743. Epub 2022 May 11.

Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20100, Milan, Italy.

Data concerning the efficacy of SARS-CoV-2 vaccines in patients with non-oncological hematologic conditions are lacking. These include autoimmune cytopenias (autoimmune hemolytic anemia AIHA, immune thrombocytopenia ITP, and autoimmune neutropenia), and bone marrow failure syndromes (aplastic anemia, low risk myelodysplastic syndromes, and paroxysmal nocturnal hemoglobinuria). These conditions may relapse/reactivate after COVID-19 infection and vaccine. Read More

View Article and Full-Text PDF

Mimic or Coincidentally? TAFRO Syndrome and Systemic Lupus Erythematosus: A Case-Based Review.

Mod Rheumatol Case Rep 2022 May 11. Epub 2022 May 11.

Division of Rheumatology, Department of Internal Medicine, Kahramanmaraş Sütçü İmam University Faculty of Medicine, Onikişubat/Kahramanmaraş, Turkey.

Introduction: Castleman's Disease (CD) is a rare, systemic disease with histopathological features of angiofollicular lymph node hyperplasia. In the literature, there are case-level reports that mimic or coexist with Systemic Lupus Erythematosus (SLE) clinically and laboratoryly. Is this condition two separate diseases or is it an imitation of each other?

Case Presentation: A 73-year-old female patient was admitted to our clinic with arthritis, lymphadenopathy (LAP), fever, weight loss and malar rash. Read More

View Article and Full-Text PDF

The Extensive Regulation of MicroRNA in Immune Thrombocytopenia.

Clin Appl Thromb Hemost 2022 Jan-Dec;28:10760296221093595

Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.

MicroRNA (miRNA) is a small, single-stranded, non-coding RNA molecule that plays a variety of key roles in different biological processes through post-transcriptional regulation of gene expression. MiRNA has been proved to be a variety of cellular processes involved in development, differentiation, signal transduction, and is an important regulator of immune and autoimmune diseases. Therefore, it may act as potent modulators of the immune system and play an important role in the development of several autoimmune diseases. Read More

View Article and Full-Text PDF

A Rare Case of Systemic Lupus Erythematosus Manifesting as Genital Ulcers.

Cureus 2022 Apr 4;14(4):e23818. Epub 2022 Apr 4.

Obstetrics and Gynecology, SSIMS & RC, Davangere, IND.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems. In this report, we discuss the case of a patient with a history of idiopathic thrombocytopenic purpura (ITP), hypothyroidism, SLE, and Crohn's disease (CD) who presented to the emergency room with fever, burning micturition, abdominal pain, and perineal ulcers. Upon subsequent treatment for urinary tract infections (UTI) and negative evaluations for an infectious cause of genital ulcers like sexually transmitted diseases, the etiology of ulcers was found to be SLE. Read More

View Article and Full-Text PDF

[Expression of miR-106b-5p in children with primary immune thrombocytopenia and its correlation with T cells].

Zhongguo Dang Dai Er Ke Za Zhi 2022 Apr;24(4):411-416

Department of Clinical Laboratory, Haikou Maternal and Child Health Hospital, Haikou 570100, China.

Objectives: To study the expression level of plasma miR-106b-5p in primary immune thrombocytopenia (ITP) and its correlation with the levels of T helper 17 cell (Th17) and regulatory T cell (Treg) and the Th17/Treg ratio.

Methods: A total of 79 children with ITP (ITP group) and 40 healthy children (control group) were selected as subjects. According to the treatment response, the 79 children with ITP were divided into three groups: complete response (=40), partial response (=18), and non-response (=21). Read More

View Article and Full-Text PDF

Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.

Vaccine 2022 May 27;40(24):3305-3312. Epub 2022 Apr 27.

Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Public Health Ontario, ON, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada. Electronic address:

Background: Background incidence rates are critical in pharmacovigilance to facilitate identification of vaccine safety signals. We estimated background incidence rates of 11 adverse events of special interest related to COVID-19 vaccines in Ontario, Canada.

Methods: We conducted a population-based retrospective observational study using linked health administrative databases for hospitalizations and emergency department visits among Ontario residents. Read More

View Article and Full-Text PDF

Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review.

Clin Rheumatol 2022 May 7. Epub 2022 May 7.

Department of Rheumatology and Immunology, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, 400042, China.

Thrombotic thrombocytopenic purpura (TTP), a life-threatening syndrome characterized by acute microangiopathic hemolytic anemia, thrombocytopenia, and visceral ischemia, can be classified as congenital TTP (inherited due to a mutation in ADAMTS13) and acquired TTP. The acquired TTP is further classified as idiopathic and secondary TTP. Systemic lupus erythematosus (SLE) is regarded as one of the most common causes of secondary TTP (SLE-TTP). Read More

View Article and Full-Text PDF

A very rare case of splenosis and acquired chronic non-cirrhotic portal vein thrombosis with cavernous transformation.

Clin Case Rep 2022 May 4;10(5):e05799. Epub 2022 May 4.

Department of Hospital Internal Medicine, Occupational Pathology with a Course of Hematology I.K. Akhunbaev Kyrgyz State Medical Academy Bishkek Kyrgyzstan.

We present a clinical case of a young woman who underwent splenectomy for thrombocytopenic splenomegaly at the age of 7 years. An acute diagnostic picture of splenosis of the left epigastric region and chronic non-cirrhotic portal vein thrombosis with cavernous transformation was found 20 years later. Read More

View Article and Full-Text PDF

Fuchs Syndrome with Isolated Oral Mucosa Lesions due to Severe Herpes Simplex Cheilitis in a Patient with Idiopathic Thrombocytopenic Purpura.

Eur J Case Rep Intern Med 2022 4;9(4):003278. Epub 2022 Apr 4.

Thun General Hospital, Thun, Switzerland.

Stevens-Johnson syndrome (SJS) is a severe dermatological disease classically characterized by erythematous target lesions and mucosal involvement. Fuchs syndrome is an incomplete presentation of SJS which has oral, conjunctival and genital manifestations but no skin lesions. To the best of our knowledge, our case of Fuchs syndrome in an 80-year-old man is the first such case related to herpes simplex virus (HSV)-1 infection to be described. Read More

View Article and Full-Text PDF

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma.

Front Immunol 2022 20;13:871217. Epub 2022 Apr 20.

Department of Medical Oncology, University Hospital Waterford, Waterford, Ireland.

A man in his early 50s presented with small bowel obstruction, requiring emergency laparoscopic small bowel resection for the metastatic melanoma of the jejunum with no identifiable primary lesion. One week after his first treatment with ipilimumab and nivolumab, he presented with diffuse abdominal pain, constipation, and fatigue. A computerized tomography scan did not identify a cause for his symptoms. Read More

View Article and Full-Text PDF

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies.

Front Immunol 2022 19;13:863177. Epub 2022 Apr 19.

Department of Pediatrics, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, United States.

Management of refractory immune thrombocytopenia frequently involves rituximab, a chimeric anti-CD20 monoclonal antibody, to target B cells and induce remission in most patients. However, neutralizing antibodies to rituximab that nullify therapeutic response and may lead to serum sickness have been rarely reported. Here, we present a case of a young adult woman with Evans syndrome treated with rituximab, complicated by the development of serum sickness, acute respiratory distress syndrome, and platelet refractoriness presumed secondary to neutralizing antibodies to rituximab. Read More

View Article and Full-Text PDF

Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT).

Semin Hematol 2022 Apr 23;59(2):97-107. Epub 2022 Feb 23.

Institute for Anatomy and Cell Biology, University Medicine Greifswald, Greifswald, Germany.

Vaccine-induced immune thrombotic thrombocytopenia (VITT; synonym, thrombosis with thrombocytopenia syndrome, is associated with high-titer immunoglobulin G antibodies directed against platelet factor 4 (PF4). These antibodies activate platelets via platelet FcγIIa receptors, with platelet activation greatly enhanced by PF4. Here we summarize the current concepts in the pathogenesis of VITT. Read More

View Article and Full-Text PDF

Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT).

Semin Hematol 2022 Apr 7;59(2):89-96. Epub 2022 Mar 7.

Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; McMaster Center for Transfusion Research, McMaster University, Hamilton, Ontario, Canada; Service of Benign Hematology, Department of Medicine, Hamilton Health Sciences, Hamilton, Ontario Canada; Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Transfusion Medicine, Hamilton Regional Laboratory Medicine Program, Hamilton, Ontario, Canada. Electronic address:

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a novel prothrombotic disorder characterized by thrombosis, thrombocytopenia, and disseminated intravascular coagulation identified in hundreds of recipients of ChAdOx1 nCoV-19 (Oxford/AstraZeneca), an adenovirus vector coronavirus disease 2019 (COVID-19) vaccine. VITT resembles heparin-induced thrombocytopenia (HIT) in that patients have platelet-activating anti-platelet factor 4 antibodies; however, whereas heparin typically enhances platelet activation by HIT antibodies, VITT antibody-induced platelet activation is often inhibited in vitro by pharmacological concentrations of heparin. Further, the thrombotic complications in VITT feature much higher frequencies of atypical thrombosis, most notably cerebral vein thrombosis and splanchnic vein thrombosis, compared with HIT. Read More

View Article and Full-Text PDF

Laboratory testing for VITT antibodies.

Semin Hematol 2022 Apr 7;59(2):80-88. Epub 2022 Mar 7.

Institute for Transfusion Medicine, University Medicine Greifswald, Greifswald, Germany.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a highly prothrombotic disorder that like heparin-induced thrombocytopenia (HIT) is caused by platelet-activating antibodies that recognize platelet factor 4 (PF4). However, unlike HIT-where heparin at low concentrations (0.1-0. Read More

View Article and Full-Text PDF

Clinical picture of VITT.

Semin Hematol 2022 Apr 8;59(2):76-79. Epub 2022 Feb 8.

Department Hematology, Oxford University Hospitals NHS Foundation Trust, Oxfordshire. Electronic address:

This chapter explores the clinical features of vaccine-induced immune thrombotic thrombocytopenia, also called vaccine-induced immune thrombocytopenia and thrombosis (VITT). Whilst the etiology is distinct from other causes of thrombotic thrombocytopenia syndrome (TTS), presentation may be similar and hence the need for strict diagnostic criteria to ensure accurate and prompt diagnosis and early treatment. Studies have identified prognostic markers of the disease, directing therapy and management pathways, and mortality and morbidity from this rare but life-threatening and potentially disabling consequence of the ChAdOx1 nCov-19 vaccine has declined. Read More

View Article and Full-Text PDF

Epidemiology of VITT.

Authors:
Menaka Pai

Semin Hematol 2022 Apr 8;59(2):72-75. Epub 2022 Feb 8.

McMaster University, Hamilton Health Sciences, Hamilton Regional Laboratory Medicine Program, Hamilton, Ontario, Canada. Electronic address:

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a life-threatening syndrome of aggressive thrombosis, often profound thrombocytopenia, and frequently overt disseminated intravascular coagulation. It has been associated with 2 adenovirus vector COVID-19 vaccines: ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2. Read More

View Article and Full-Text PDF

Platelet-activating anti-PF4 disorders: An overview.

Semin Hematol 2022 Apr 20;59(2):59-71. Epub 2022 Feb 20.

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada; Transfusion Medicine, Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada; Service of Benign Hematology, Hamilton Health Sciences, Hamilton General Hospital, Hamilton, ON, Canada; McMaster Center for Transfusion Research, McMaster University, Hamilton, ON, Canada. Electronic address:

Platelet factor 4 (PF4) is a highly cationic tetrameric protein that can be targeted by platelet-activating anti-PF4 antibodies of immunoglobulin G (IgG) class. Certain features of PF4, including its multivalent nature (duplicate antigen sites per tetramer), the ability of many PF4 tetramers to undergo close approximation through charge neutralization, and the dimeric binding of IgG molecules, results in formation of IgG-containing immune complexes in situ on platelets, neutrophils, and monocytes, resulting in Fcγ receptor-mediated pancellular activation that also activates hemostasis (potential for disseminated intravascular coagulation). This review discusses 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia ([HIT]; triggered by heparin and certain other polyanionic pharmaceuticals, featuring predominantly heparin-dependent antibodies), autoimmune HIT (aHIT; severe subtype of HIT that features both heparin-dependent and heparin-independent platelet-activating antibodies), and spontaneous HIT (non-heparin triggers such as knee replacement surgery and infection; predominantly heparin-independent platelet-activating antibodies). Read More

View Article and Full-Text PDF

Vaccine-induced immune thrombotic thrombocytopenia (VITT).

Semin Hematol 2022 Apr 8;59(2):57-58. Epub 2022 Mar 8.

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Transfusion Medicine, Hamilton Regional Laboratory Medicine Program, Hamilton, Ontario, Canada; Service of Benign Hematology, Hamilton Health Sciences, Hamilton General Hospital, Hamilton, Ontario, Canada; McMaster Center for Transfusion Research, McMaster University, Hamilton, Ontario, Canada; McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario. Electronic address:

View Article and Full-Text PDF

The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT).

Semin Hematol 2022 Apr 18;59(2):115-119. Epub 2022 Feb 18.

Department Hematology, Oxford University Hospitals NHS Foundation Trust, UK.

This review paper explores the potential psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia, also called vaccine-induced immune thrombocytopenia, and thrombosis (VITT). In the absence of any literature to date we have extrapolated data from similar conditions, particularly data pertaining to the critical care population. We discuss both the direct and indirect effects of thrombosis, likely psychiatric and psychological challenges during recovery, and ethical issues around vaccination. Read More

View Article and Full-Text PDF

Longitudinal Aspects of VITT.

Semin Hematol 2022 Apr 7;59(2):108-114. Epub 2022 Mar 7.

Department of Transfusion Medicine, Institute of Immunology and Transfusion Medicine, Universitätsmedizin Greifswald, Greifswald, Germany. Electronic address:

In hundreds of patients worldwide, vaccination against COVID-19 with adenovirus vector vaccines (ChAdOx1 nCoV-19; Ad26.COV2.S) triggered platelet-activating anti-platelet factor 4 (PF4) antibodies inducing vaccine-induced immune thrombotic thrombocytopenia (VITT). Read More

View Article and Full-Text PDF

Severe immune thrombocytopenia following diphtheria, tetanus, pertussis and polio vaccination in a 36-year-old Caucasian woman: a case report.

Eur J Med Res 2022 May 3;27(1):63. Epub 2022 May 3.

Department of Internal Medicine II, Center for Complementary Medicine, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany.

Background: Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by low platelet counts and increased bleeding risk. The disease may be induced by other disorders, including malignancies, autoimmune diseases, infectious agents or drugs. However, ITP has also been described following vaccinations, such as the measles-mumps-rubella vaccination. Read More

View Article and Full-Text PDF

Mitomycin-Induced Thrombotic Thrombocytopenic Purpura Treated Successfully With Plasmapheresis and Steroid: A Case Report.

Cureus 2022 Mar 26;14(3):e23525. Epub 2022 Mar 26.

Pulmonary and Critical Care, Icahn School of Medicine at Mount Sinai/BronxCare Health System, New York City, USA.

Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy (TMA) caused by severely reduced ADAMTS13 or the von Willebrand factor-cleaving protease (VWFCP) enzyme resulting in low platelet and red blood cell counts along with severe renal, cardiac, and neurological dysfunction. Plasmapheresis is the treatment of choice. Mitomycin, a widely used chemotherapeutic agent for gastrointestinal (GI) cancers anal and breast cancers, has been reported to occasionally cause severe TTP and hemolytic uremic syndrome (HUS) cases. Read More

View Article and Full-Text PDF

Second-dose VITT: rare but real.

Blood 2022 Apr;139(17):2581-2583

University of Sheffield.

View Article and Full-Text PDF

Pathogenesis of Autoimmune Cytopenias in Inborn Errors of Immunity Revealing Novel Therapeutic Targets.

Front Immunol 2022 6;13:846660. Epub 2022 Apr 6.

Paediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, ASST- Spedali Civili of Brescia, University of Brescia, Brescia, Italy.

Autoimmune diseases are usually associated with environmental triggers and genetic predisposition. However, a few number of autoimmune diseases has a monogenic cause, mostly in children. These diseases may be the expression, isolated or associated with other symptoms, of an underlying inborn error of immunity (IEI). Read More

View Article and Full-Text PDF

Investigation of the correlation between immune thrombocytopenia and T cell activity-regulated gene polymorphism using functional study.

Sci Rep 2022 Apr 22;12(1):6601. Epub 2022 Apr 22.

Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan City, 333, Taiwan, ROC.

Thrombocytopenia is a condition where the platelet count is under 100 × 10/L, which is caused by various disorders. However, the mechanism of thrombocytopenia is still unclear. Hence, we tried to investigate the correlation between immune thrombocytopenia (ITP) and single nucleotide polymorphisms (SNPs) of genes related to T cell activation. Read More

View Article and Full-Text PDF

Association of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia.

Front Immunol 2022 1;13:810620. Epub 2022 Apr 1.

Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.

Thrombocytopenia is a multifactorial condition that frequently involves concomitant defects in platelet production and clearance. The physiopathology of low platelet count in thrombocytopenia remains unclear. Sialylation on platelet membrane glycoprotein and follicular helper T cells (TFHs) are thought to be the novel platelet clearance pathways. Read More

View Article and Full-Text PDF

Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium.

PLoS One 2022 21;17(4):e0267342. Epub 2022 Apr 21.

Division of Hematology and Oncology, Cantonal Hospital, Münsterlingen, Switzerland.

Aims Of The Study: Thrombopoietin receptor agonists (TPO-RAs) are approved for immune thrombocytopenia (ITP), but their impact on health-related quality of life (HRQoL) remains poorly investigated in clinical practice. This observational study aimed to gain insight into real-world patient-reported experiences of the burden of ITP and TPO-RAs.

Method: An online questionnaire of closed questions was used to collect views of patients with primary ITP from Switzerland, Austria, and Belgium, between September 2018 and April 2020. Read More

View Article and Full-Text PDF